Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment

BACKGROUND: Imatinib is a highly effective drug in up-front treatment of chronic myeloid leukemia (CML). In children impaired longitudinal growth has been reported as side effect exerted by this drug under prolonged therapy. We therefore prospectively evaluated alterations of bone biochemical marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaeger, Bernadette Anna Sophia, Tauer, Josephine Tabea, Ulmer, Anna, Kuhlisch, Eberhard, Roth, Heinz Juergen, Suttorp, Meinolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2012
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560809/
https://www.ncbi.nlm.nih.gov/pubmed/23197234
http://dx.doi.org/10.12659/MSM.883599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560809/
https://www.ncbi.nlm.nih.gov/pubmed/23197234
http://dx.doi.org/10.12659/MSM.883599

Ejemplares similares